Randomised controlled trials (RCTs) of patients that underwent elective percutaneous coronary intervention to statin therapy versus placebo or standard care were eligible for inclusion. In included trials, statin was required to be initiated around the time of coronary intervention, with individual outcome data. Trials performed entirely in the setting of unstable angina or acute myocardial infarction were excluded.
The mean age of patients was 58.3 to 64.5 years and the proportion of males ranged from 82.5 to 86.7% in the included trials. The statins evaluated were pravastatin, fluvastatin, atorvastatin and simvastatin, at doses that ranged from 20 to 80 mg per day. The majority of trials compared this with placebo. Statins were initiated from 31 days before to 22 days after percutaneous coronary intervention. Follow-up varied from less than 24 hours to 45 months (median) in the included trials.
The primary end point evaluated was myocardial infarction. Secondary end-points were all-cause mortality, cardiovascular mortality, surgical or percutaneous revascularisation and stroke.
The authors did not state how the papers were selected for the review, or how many reviewers performed the selection.